{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:24:25Z","timestamp":1790706265576,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":3622,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1111\/j.1600-6143.2012.04281.x","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T15:59:19Z","timestamp":1349107159000},"page":"100-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation"],"prefix":"10.1016","volume":"13","author":[{"given":"T.","family":"Isakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Messinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Scialla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"G.W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Z.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mucsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1600-6143.2012.04281.x_bib1","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1056\/NEJMon043418","article-title":"Transplantation 50 years later\u2014progress, challenges, and promises","volume":"351","author":"Sayegh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra0902927","article-title":"Rejection of the kidney allograft","volume":"363","author":"Nankivell","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib3","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib4","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US study group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients","volume":"2","author":"Morales","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00007890-200109150-00007","article-title":"Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure","volume":"72","author":"Johnson","year":"2001","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib9","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-6143.2011.03826.x","article-title":"Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin","volume":"12","author":"Cortazar","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1681\/ASN.2010080819","article-title":"Racial ethnic differences in rates and determinants of deceased donor kidney transplantation","volume":"22","author":"Hall","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00007890-199201000-00011","article-title":"Analyses of the UNOS Scientific Renal Transplant Registry at three years\u2014early events affecting transplant success","volume":"53","author":"Cecka","year":"1992","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00007890-199305000-00007","article-title":"Early versus late acute renal allograft rejection: Impact on chronic rejection","volume":"55","author":"Basadonna","year":"1993","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution\u2014a simulation study","volume":"172","author":"Sturmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/sim.1438","article-title":"Analysis of clustered matched-pair data","volume":"22","author":"Durkalski","year":"2003","journal-title":"Stat Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1541-0420.2005.00389.x","article-title":"The Wilcoxon signed rank test for paired comparisons of clustered data","volume":"62","author":"Rosner","year":"2006","journal-title":"Biometrics"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib22","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2011010006","article-title":"Randomized trial of immunosuppressive regimens in renal transplantation","volume":"22","author":"Guerra","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib23","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1600-6143.2011.03919.x","article-title":"Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial","volume":"12","author":"Abdelmalek","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib25","unstructured":"Information for Healthcare Professionals: Sirolimus (marketed as Rapamune). FDA ALERT [06\/11\/2009]. Available at: http:\/\/wwwfdagov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm165015htm. Accessed April 3, 2012."},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1600-6143.2011.03922.x","article-title":"Sirolimus conversion for renal dysfunction in liver transplant recipients: The devil really is in the details","volume":"12","author":"McKenna","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-6143.2006.01658.x","article-title":"Mycophenolate mofetil\/sirolimus compared to other common immunosuppressive regimens in kidney transplantation","volume":"7","author":"Srinivas","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: New-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/01.tp.0000185200.17589.74","article-title":"Proteinuria following a switch from calcineurin inhibitors to sirolimus","volume":"80","author":"Letavernier","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib32","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1432-2277.2011.01357.x","article-title":"Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials","volume":"24","author":"Pengel","year":"2011","journal-title":"Transplant Int"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib33","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/TP.0b013e3181b9d0da","article-title":"Prospective observational study of sirolimus as primary immunosuppression after renal transplantation","volume":"88","author":"Pescovitz","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib35","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib36","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib37","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0002-9343(88)90302-6","article-title":"Risk factors for accelerated atherosclerosis in renal transplant recipients","volume":"84","author":"Kasiske","year":"1988","journal-title":"Am J Med"},{"key":"10.1111\/j.1600-6143.2012.04281.x_bib38","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-6143.2012.04281.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522257724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522257724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-6143.2012.04281.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:58:23Z","timestamp":1761627503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522257724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1600613522257724"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04281.x","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04281.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}